Company news
Cingulate Inc. news in 2023
Cingulate Inc.'s news releases, calls and decks from 2023, newest first.
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)
November 30, 2023
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
November 12, 2023
Cingulate Announces Closing of $4.0 Million Public Offering
September 12, 2023
Cingulate Announces Pricing of $4.0 Million Public Offering
September 10, 2023
Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
September 10, 2023
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
September 4, 2023
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
August 13, 2023
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
July 10, 2023
Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
June 28, 2023
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
June 7, 2023
Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
May 9, 2023
Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO
May 2, 2023
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
April 3, 2023
Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301
March 12, 2023
Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update
March 9, 2023
Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD
February 22, 2023
Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD
January 3, 2023
Decks in 2023
- Investor Presentation (October 2023)
Investor deck · 30 slides · Oct 19, 2023
- Investor Presentation (January 2023)
Investor deck · 21 slides · Jan 9, 2023